Evotec had to announce a setback recently when its Alzheimer’s treatment in collaboration with Roche failed in Phase IIb. However, another strong partner on its side, Sanofi, never lost trust in the German biotech’s value. In the last three days, the French giant entered into two new projects with Evotec, which target diabetes and immuno-oncology. All in all, Evotec could cash in up to €500M.
In recent years, immuno-oncology has emerged as a particularly promising field to create potentially curative treatment options for many cancer patients. With this in mind, Sanofi, Evotec and the Austrian Apeiron Biologics AG joined forces. Together, they aim to treat solid and hematopoietic cancers by enhancing the anti-tumor activity of human lymphocytes.
Further, using Evotec’s drug discovery technology and Apeiron Biologic’s immunological know-how, the companies want to find new small molecule and their targets for next-generation therapies in immuno-oncology. These are expected to complement the current offerings of checkpoint inhibitors. Both companies share Sanofi’s promised milestone payments of up to €200M as well as potential royalties.